Breaking News Instant updates and real-time market news.

XENE

Xenon Pharmaceuticals

$12.20

(0.00%)

06:11
08/29/18
08/29
06:11
08/29/18
06:11

Xenon Pharmaceuticals' XEN1101 shows 'positive' results in Phase 1b study

Xenon Pharmaceuticals announced 'positive' data from its XEN1101 Phase 1b transcranial magnetic stimulation study. XEN1101 is a Kv7 potassium channel opener being developed by Xenon for the treatment of epilepsy. Results will be presented in a podium presentation at the 13th European Congress on Epileptology being held in Vienna. The completed Phase 1b TMS study suggested XEN1101 has an ability to inhibit cortical excitability, an important CNS effect observed with approved anti-epileptic drugs. XEN1101 was well tolerated with all adverse events reported as mild or moderate and reversible. In addition to completing both the Phase 1a pilot and Phase 1b TMS studies, Xenon has now completed enrollment in the XEN1101 Phase 1 clinical trial using a powder-in-capsule formulation, which is evaluating the safety, tolerability and pharmacokinetics of both single ascending doses and multiple ascending doses of XEN1101. A Phase 2 clinical trial in adult focal seizures expected to be initiated in Q4.

XENE Xenon Pharmaceuticals
$12.20

(0.00%)

03/22/18
JEFF
03/22/18
NO CHANGE
Target $6
JEFF
Buy
Xenon Pharmaceuticals price target raised to $6 from $5 at Jefferies
Jefferies analyst Maury Raycroft raised his price target for Xenon Pharmaceuticals to $6 and keeps a Buy rating on the shares after traveling with management. The analyst sees 2018 as a key year for the company with data readouts in epilepsy. Initial data in May will likely move the stock, Raycroft tells investors in a research note.
06/13/18
JEFF
06/13/18
NO CHANGE
Target $9
JEFF
Buy
Sage update yesterday positive for Xenon, says Jefferies
Jefferies analyst Maury Raycroft believes Sage Therapeutics' (SAGE) FDA approval to accelerate a development path for '217 in major depressive disorder and postpartum depression provides a positive read-through for Xenon Pharmaceuticals (XENE). Xenon has two epilepsy programs and one program for hemiplegic migraine, which all have potential in rare disease indications with broader applicability, Raycroft tells investors in a research note. He believes "recent derisking" provides a "great entry point" into Xenon Pharmaceuticals at current share levels. The analyst has a Buy rating on the shares with a $9 price target.

TODAY'S FREE FLY STORIES

BHC

Bausch Health

$23.82

0.8 (3.48%)

15:45
04/25/19
04/25
15:45
04/25/19
15:45
Recommendations
Bausch Health analyst commentary  »

Bausch Health pipeline,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

NBLX

Noble Midstream

$38.92

1.49 (3.98%)

, NBL

Noble Energy

$27.51

-0.08 (-0.29%)

15:44
04/25/19
04/25
15:44
04/25/19
15:44
Periodicals
Noble Midstream put up for sale by Noble Energy, Reuters says »

Noble Midstream Partners…

NBLX

Noble Midstream

$38.92

1.49 (3.98%)

NBL

Noble Energy

$27.51

-0.08 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

INTC

Intel

$57.52

-1.2 (-2.04%)

15:40
04/25/19
04/25
15:40
04/25/19
15:40
Options
Intel options volume is 2X daily average ahead of earnings »

Intel options volume is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 16

    May

  • 03

    Jun

S

Sprint

$5.54

-0.08 (-1.42%)

, TMUS

T-Mobile

$73.06

-0.29 (-0.40%)

15:38
04/25/19
04/25
15:38
04/25/19
15:38
Periodicals
Sprint, T-Mobile officials 'cautiously optimistic' about DOJ approval, FBN says »

The U.S. Department of…

S

Sprint

$5.54

-0.08 (-1.42%)

TMUS

T-Mobile

$73.06

-0.29 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

SFLY

Shutterfly

$42.23

-0.72 (-1.68%)

15:34
04/25/19
04/25
15:34
04/25/19
15:34
Options
Shutterfly options imply 13.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

XLU

Utilities SPDR

$58.16

0.38 (0.66%)

15:30
04/25/19
04/25
15:30
04/25/19
15:30
Options
Put spreads in SPDR Utility Fund as a defensive position is adjusted »

Put spreads in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$20.19

-0.565 (-2.72%)

15:29
04/25/19
04/25
15:29
04/25/19
15:29
Hot Stocks
EQT Corporation responds to Toby Rice lawsuit »

EQT Corporation issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NBLX

Noble Midstream

$36.79

-0.64 (-1.71%)

, NBL

Noble Energy

$26.70

-0.89 (-3.23%)

15:22
04/25/19
04/25
15:22
04/25/19
15:22
Periodicals
Breaking Periodicals news story on Noble Midstream, Noble Energy »

Noble Midstream put up…

NBLX

Noble Midstream

$36.79

-0.64 (-1.71%)

NBL

Noble Energy

$26.70

-0.89 (-3.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

GM

General Motors

$39.16

-0.57 (-1.43%)

15:20
04/25/19
04/25
15:20
04/25/19
15:20
Hot Stocks
GM adds second shift, over 400 hourly jobs to Kentucky assembly plant »

General Motors said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 05

    Jun

ALKS

Alkermes

$31.49

-3.31 (-9.51%)

15:20
04/25/19
04/25
15:20
04/25/19
15:20
Recommendations
Alkermes analyst commentary at Piper Jaffray »

Piper points to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ZNGA

Zynga

$5.46

-0.125 (-2.24%)

15:20
04/25/19
04/25
15:20
04/25/19
15:20
Options
Size call spread in Zynga adjusts a bullish position »

Size call spread in Zynga…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 07

    May

  • 13

    Nov

JNPR

Juniper

$28.11

-0.615 (-2.14%)

15:19
04/25/19
04/25
15:19
04/25/19
15:19
Options
Juniper options imply 10.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
04/25/19
04/25
15:17
04/25/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
04/25/19
04/25
15:16
04/25/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADM

Archer Daniels

$42.08

-0.68 (-1.59%)

15:15
04/25/19
04/25
15:15
04/25/19
15:15
Options
Archer Daniels put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 01

    May

  • 13

    Nov

CLS

Celestica

$7.33

-1.275 (-14.82%)

15:06
04/25/19
04/25
15:06
04/25/19
15:06
Downgrade
Celestica rating change at CIBC »

Celestica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MAT

Mattel

$12.39

-0.16 (-1.27%)

15:04
04/25/19
04/25
15:04
04/25/19
15:04
Options
Mattel options imply 17.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 16

    May

  • 12

    Jun

MDP

Meredith

$58.14

-0.21 (-0.36%)

15:02
04/25/19
04/25
15:02
04/25/19
15:02
Periodicals
Authentic Brands in talks to buy Sports Illustrated from Meredith, WSJ says »

Authentic Brands has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 09

    May

  • 13

    Nov

CMG

Chipotle

$676.86

-33.14 (-4.67%)

14:59
04/25/19
04/25
14:59
04/25/19
14:59
Recommendations
Chipotle analyst commentary at Argus »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

MS

Morgan Stanley

$47.53

0.14 (0.30%)

14:58
04/25/19
04/25
14:58
04/25/19
14:58
Hot Stocks
California AG announces $150M settlement agreement with Morgan Stanley »

California Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

  • 11

    Jun

SBUX

Starbucks

$76.81

0.39 (0.51%)

14:53
04/25/19
04/25
14:53
04/25/19
14:53
Earnings
Fly Intel: What to watch in Starbucks earnings report »

Starbucks (SBUX) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AKAM

Akamai

$78.74

0.61 (0.78%)

14:53
04/25/19
04/25
14:53
04/25/19
14:53
Conference/Events
Akamai management to meet with William Blair »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 02

    May

  • 15

    May

  • 06

    Jun

AMZN

Amazon.com

$1,915.66

14.94 (0.79%)

14:50
04/25/19
04/25
14:50
04/25/19
14:50
On The Fly
Fly Intel: What to watch in Amazon earnings report »

Amazon (AMZN) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

AMP

Ameriprise

$145.43

1.475 (1.02%)

14:50
04/25/19
04/25
14:50
04/25/19
14:50
Recommendations
Ameriprise analyst commentary at Citi »

Ameriprise price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

GRUB

GrubHub

$70.14

0.84 (1.21%)

14:49
04/25/19
04/25
14:49
04/25/19
14:49
Options
GrubHub options imply 18.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

  • 28

    May

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.